EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study

Mohammad Shehab, Anwar Almajdi, Israa Abdullah, Fatema Alrashed

Frontiers in Pharmacology · 06.08.2026 · 17

DOI: 10.3389/fphar.2026.1731277 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.08.2026. Verfasst von Mohammad Shehab und 3 weiteren Autor:innen. Beteiligte Einrichtung: Program of Medicine, College of Medicine and Health Sciences, Abdullah Al Salem University, Khaldiya, Kuwait. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ustekinumab is an effective biologic therapy for inflammatory bowel disease (IBD), yet many patients experience loss of response requiring dose escalation. Predictors of ustekinumab dose escalation remain poorly defined, particularly across Crohn’s disease (CD) and ulcerative colitis (UC).

Methods

We conducted a retrospective cohort study to includ adult patients with IBD initiated on ustekinumab. The primary outcome was factors associated with dose escalation, defined as shortening ustekinumab maintenance interval to every 4 weeks, analyzed separately for CD and UC via multivariable logistic regression. The secondary outcome assessed predictors of time to escalation among CD patients using multivariable linear regression.

Results

A total of 206 patients were included (CD: 165, UC: 41). Dose escalation occurred in 69 (41.8%) of CD and 14 (34.1%) of UC patients. In CD, prior biologic use (OR 3.05; 95% CI: 1.31–7.14; p = 0.01) and prior immunomodulator use (OR 2.07; 95% CI: 1.00–4.29; p = 0.05) were significantly associated with escalation. Longer disease duration was also observed in escalated patients (median 6 vs. 4 years, p = 0.003). In UC, none of the evaluated variables predicted escalation. Median time to escalation was 9 months (IQR 3–18) in CD and 4.5 months (IQR 2–12.8) in UC. No predictors were significantly associated with time to escalation in CD subgroup analysis.

Conclusion

Prior biologic exposure, immunomodulator use, and longer disease duration predict ustekinumab dose escalation in CD but not in UC, highlighting disease-specific differences in therapeutic needs. These findings support tailored dose optimization strategies in IBD and underscore the need for prospective studies incorporating therapeutic drug monitoring and standardized escalation protocols.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseaseIBDdose escalationulcerative colitisustekinumab

Autor:innen und Institutionen

  • Program of Medicine, College of Medicine and Health Sciences, Abdullah Al Salem University, Khaldiya, Kuwait.
  • Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer, University Hospital, Jabriya, Kuwait.
  • Department of Pharmacy, The Champion Hospital, Sabah Alsalem, Kuwait.
  • Department of Pharmacy Practice, College of Pharmacy, Kuwait University, Jabriya, Kuwait.

Zitieren

APA

Shehab, M., Almajdi, A., Abdullah, I., & Alrashed, F. (2026). Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1731277

Vancouver

Shehab M, Almajdi A, Abdullah I, Alrashed F. Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1731277

BibTeX
@article{Shehab2026,
  author = {Shehab, Mohammad and Almajdi, Anwar and Abdullah, Israa and Alrashed, Fatema},
  title = {Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1731277}
}
Kostenlos starten →